BJ,
Peter had said this was the way they were going. They said
they were looking at a number of companies and felt they
would split Europe up.
At that time he mentioned Germany, France, Italy, Spain,
and I forget the fifth country.
Now it appears they're going richest first which my searches
a couple of months ago agree with. I believe that's why
Spain has apparently been replaced by Sweden.
What troubles me is that Switzerland is not part of the EU.
The European Union is:
Austria
Belgium
Denmark
Finland
France
Germany
Greece
Ireland
Italy
Luxembourg
Netherlands
Portugal
Spain
Sweden
United Kingdom of Great Britain and Northern Ireland
She said in the DJN interview:
In a news release, Dimethaid said it will immediately seek approvals for PENNSAID from other European Union countries. Under the mutual recognition procedure prevailing in the EU, the U.K. will act as agent for other EU member states, who can recognize this approval and issue their own authorizations.
"Because the British regulatory agency is so well-recognized in Europe, we don't anticipate any negative responses when they submit on our behalf to the other countries," Keeler said, noting that submissions for approval will be made in January to Germany, France, Italy, Sweden and Switzerland, with other European countries to follow.
Submissions in January. We could have a good collection of
these by May. I estimated Germany and France together as
3 times the size of the British market. Between them they
have a population just below 150 million people with rich
medical coverage.
As Peter said, of the finalists in the negotiations, they
would probably pick a UK partner and a european partner.
How they actually end up slicing the pie I'm not sure, but,
its unlikely we won't get at least 2 partners out of this
round of negotiations.
Mathematically, the UK at around 55 million plus is a
600 million dollar market (Peter had said 20% was topical)
and the other big two should bring that up to around
2.4 billion Cdn (euro is lower but medical spending is
richer).
Should be plenty of opportunity for sales growth hopefully
beginning in March, but looking good for the summer.
Going head to head with the oral's I hope refers to sales
effort and not labelling limitation. I don't see that.
As Pennsaid establishes that it truly works (and works
well), it should naturally start encroaching on Oral
NSAID sales.
We've been waiting for the revenue game for a long time,
and I am looking forward to early 2002 calendar, when EPS
drive this stock past where I need it regardless of
analysts and their piniata predictions.
To all,
Further to my comments on portfolio returns which John
replied to - I came in in 1998.
A compounded 50% rate of return on that would be a $26
stock price June 02, 2002.
As I've been saying all along, I expect much more. The
high dollar buy's were all this year and so will also
exceed that rate if I see that price by that date.
Investors need to decide what they're measuring. That's
both values and timelines. If you haven't, write down
on a piece of paper what you expect and by when. Then
ask yourself how probable that is. Once you get a number
you also feel is probable by your date, stop watching the
stock price and concentrate on understanding the story and
events better. (Of course that's more for longer term investors).
This promotes good kharma.
We're a year late. Yup. And I can live with that.
Everybody has their own style. Mine is very long term.
(I wasn't kidding Mark/Olga).
Wolf |
